Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
- Resource Type
- Article
- Authors
- Ahmed, Anwar; Aiba, Ikuko; Albanese, Alberto; Bertram, Kelly; Bordelon, Yvette; Bower, James; Brosch, Jared; Claassen, Daniel; Colosimo, Carlo; Corvol, Jean-Christophe; Cudia, Paola; Daniele, Antonio; Defebvre, Luc; Driver-Dunckley, Erika; Duquette, Antoine; Eleopra, Roberto; Eusebio, Alexandre; Fung, Victor; Geldmacher, David; Golbe, Lawrence; Grandas, Francisco; Hall, Deborah; Hatano, Taku; Höglinger, Günter U; Honig, Lawrence; Hui, Jennifer; Kerwin, Diana; Kikuchi, Akio; Kimber, Thomas; Kimura, Takashi; Kumar, Rajeev; Litvan, Irene; Ljubenkov, Peter; Lorenzl, Stefan; Ludolph, Albert; Mari, Zoltan; McFarland, Nikolaus; Meissner, Wassilios; Mir Rivera, Pablo; Mochizuki, Hidek; Morgan, John; Munhoz, Renato; Nishikawa, Noriko; O`Sullivan, John; Oeda, Tomoko; Oizumi, Hideki; Onodera, Osamu; Ory-Magne, Fabienne; Peckham, Elizabeth; Postuma, Ronald; Quattrone, Aldo; Quinn, Joseph; Ruggieri, Stefano; Sarna, Justyna; Schulz, Paul E; Slevin, John; Tagliati, Michele; Wile, Daryl; Wszolek, Zbigniew; Xie, Tao; Zesiewicz, Theresa; Mendonca, Nuno; Wang, Deli; Zheng, Hui; Rendenbach-Mueller, Beatrice; Lon, Hoi-Kei; Jin, Ziyi; Fisseha, Nahome; Budur, Kumar; Gold, Michael; Ryman, Davis; Florian, Hana
- Source
- In The Lancet Neurology March 2021 20(3):182-192
- Subject
- Primary Research
Articles
- Language
- ISSN
- 1474-4422